Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of liposomal irinotecan + S-1 versus liposomal irinotecan + 5-fluorouracil/leucovorin in second-line metastatic pancreatic cancer
NL-OMON59803Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing liposomal irinotecan + S-1 with liposomal irinotecan + 5-fluorouracil/leucovorin (2 arms). Primary endpoint: Progression-free survival. Started Nov 2019; status: completed.
02
Drugs
nanoliposomal irinotecantegafurfluorouracilfolinic acid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON59803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59803.